- May 27, 2021
Grapheal is a young MedTech company based in Grenoble (France) that addresses unmet needs in medical diagnostics. Its mission is to create a new generation of biosensors for real-time and affordable diagnostics by merging digital biosensing with wireless near-field communication. This new class of wirelessly connected biosensors opens the door to many new applications relying on instant and direct detection of biomolecules without molecular amplification. It supports accurate and informed decisions in a decentralized healthcare system by empowering caregivers, professionals, and everyday users. Since its creation in 2019, Grapheal received numerous innovation awards, including the French i-Lab and i-Nov prizes, EDF Pulse prize, and EU-funded EIT Health Headstart award.
These new embedded biosensing systems are made for fast on-site diagnosis or real-time remote patient monitoring. It features novel biocompatible nanomaterials, flexible embedded electronics, software data analysis, and medical cloud technologies. By exploiting graphene’s uniquely high electrical conductivity, it is possible to detect biomolecules at a low level, without signal amplification before detection. During the last six months, Grapheal has finalized the design of two products addressing different markets: a new generation digital COVID-19 test directly coupled to a sanitary Pass (TestNPass) and a wound care digital assistant (WoundLAB) to improve the monitoring of hard-to-heal wounds.
WoundLAB is a flexible and transparent graphene-based biosensor patch that continuously records and stores wound biochemical parameters. A smartphone app communicates these data to a telemedicine cloud for data aggregation and analysis. This solution allows caregivers to monitor wound healing remotely, prompting alerts if any infections or medical complications arise.
TestNPass is Grapheal’s ultra-rapid digital Covid test that is easy to implement anywhere for high-flow screening. Within 5 minutes, the digital test detects the presence of the virus without the requirement of dedicated reading equipment other than a smartphone or a standard NFC-connected device. The test result is tamper-proof and encrypted into an NFC tag to constitute a standalone biometric access control pass. A Phase I Clinical trial of this Grapheal product in its final stage at the university hospital of Grenoble. For more information, please visit www.grapheal.com.